STAT3 and nonpapillary renal cell carcinoma: Sorafenib, a tyrosine kinase inhibitor often used to treat ccRCC, is one that has been shown to independently cause muscle and fat loss, possibly via hyperactiviation of STAT3 and ERK at the muscle [46].